S3 Table. Baseline characteristics and clinical outcomes of the 32 patients with severe COVID-19 according to dexamethasone use.

|  | Dexamethasone    | No dexamethasone |         |
|--|------------------|------------------|---------|
|  | (n = 20)         | (n = 12)         | Р       |
| Baseline characteristics               |                  |                  |         |
| Age, years                             | 70 (59–75)       | 69 (60–79)       | 0.953   |
| Male sex                               | 11 (55)          | 6 (50)           | 0.784   |
| Body mass index, kg/m <sup>2</sup>     | 26.9 (23.4–31.0) | 22.0 (20.7–24.0) | 0.001   |
| Smoking status                         |                  |                  | 0.198   |
| Ever smoker                            | 7 (35)           | 7 (58)           |         |
| Never smoker                           | 13 (65)          | 5 (42)           |         |
| Comorbidities                          |                  |                  |         |
| Diabetes                               | 8 (40)           | 0                | 0.014   |
| Hypertension                           | 12 (60)          | 6 (50)           | 0.581   |
| Chronic lung disease                   | 5 (25)           | 2 (17)           | 0.683   |
| Liver cirrhosis                        | 1 (5)            | 0                | >0.99   |
| Malignancy                             | 1 (5)            | 0                | >0.99   |
| Charlson Comorbidity Index             | 3.0 (2.0-4.0)    | 3.0 (1.5–3.5)    | 0.460   |
| Time from symptom onset to day 1, days | 8 (7–10)         | 9 (4–11)         | 0.891   |
| ARDS                                   | 5 (25)           | 2 (17)           | 0.683   |
| qSOFA score                            | 1 (0–1)          | 1 (0–1)          | 0.966   |
| Type of oxygen support                 |                  |                  | < 0.001 |
| Mechanical ventilation                 | 5 (25)           | 1 (8)            |         |
| High-flow nasal cannula                | 11 (55)          | 0                |         |
| Supplemental oxygen                    | 4 (20)           | 11 (92)          |         |
| Remdesivir                             | 11 (55)          | 0                | 0.002   |
| Vital signs and laboratory data        |                  |                  |         |
| Body temperature, °C                   | 37.8 (37.4–38.6) | 38.0 (37.3–38.3) | 0.640   |
| Mean blood pressure, mmHg              | 84 (74–96)       | 80 (71–89)       | 0.391   |
| Heart rate, beats/min                  | 89 (76–95)       | 83 (79–88)       | 0.508   |
| Respiratory rate, breaths/min          | 21 (20–24)       | 20 (20–24)       | 0.735   |
| SpO <sub>2</sub> /FiO <sub>2</sub>     | 196 (172–272)    | 377 (291–408)    | < 0.001 |
| Creatinine, mg/dL                      | 0.7 (0.6–0.8)    | 0.8 (0.6–0.8)    | 0.654   |
| White cell count, 1000/mm <sup>3</sup> | 7.0 (4.2–8.3)    | 4.8 (3.4–5.8)    | 0.039   |
| Total bilirubin, mg/dL                 | 0.7 (0.5–1.0)    | 0.6 (0.5–0.8)    | 0.410   |
| Lactate dehydrogenase, IU/L            | 408 (313–470)    | 357 (254–434)    | 0.259   |
| C-reactive protein, mg/L               | 111 (65–183)     | 47 (18–92)       | 0.014   |
| Glucose, mg/dL                         | 141 (118–199)    | 116 (102–128)    | 0.037   |
| Radiologic score                       | 5 (3–6)          | 2 (1–4)          | 0.006   |
| Cycle threshold value                  | 25.1 (20.7–28.7) | 25.9 (19.7–29.8) | 0.815   |
| Clinical outcomes                      |                  | ·                |         |
| Oxygen-free days at day 28             | 13.5 ± 8.9       | 13.3 ± 9.3       | 0.723   |
| Length of hospital stay, days          | 21.9 ± 16.7      | 16.3 ± 4.3       | 0.666   |
| Hospital mortality                     | 1 (5)            | 0                | >0.99   |
| Superinfection                         | 2 (10)           | 0                | 0.516   |

Data are presented as number (%), mean  $\pm$  standard deviation, or median (interquartile range). The P-values were calculated using the Mann-Whitney U test for continuous variables and using the chi-squared test or Fisher's exact test for categorical variables.

ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease 2019; FiO<sub>2</sub>, fraction of inspired oxygen; SpO<sub>2</sub>, pulse oximetric saturation; qSOFA, quick Sequential Organ Failure Assessment.